
==== Front
BMC Gastroenterol
BMC Gastroenterol
BMC Gastroenterology
1471-230X
BioMed Central London

39237899
3394
10.1186/s12876-024-03394-6
Research
Association between neutrophil-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in the US population: a nationally representative cross-sectional study using NHANES data from 2017 to 2020
Lu Yangni 1
Xu Xianli 1
Wu Jianlin 1
Ji Lei 1
Huang Huiya 2
Chen Maowei chenmaowei2008@163.com

1
1 https://ror.org/03dveyr97 grid.256607.0 0000 0004 1798 2653 Department of Infectious Diseases, Wuming Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi China
2 https://ror.org/03dveyr97 grid.256607.0 0000 0004 1798 2653 Department of General Medicine, Wuming Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi China
5 9 2024
5 9 2024
2024
24 30023 4 2024
29 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

The neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) has emerged as a promising biomarker for assessing inflammation and lipid dysregulation. Increasing evidence indicates that these metabolic disturbances play a crucial role in the development of metabolic dysfunction-associated steatotic liver disease(MASLD). This study aims to investigate the association between NHR, MASLD, and liver fibrosis.

Methods

This cross-sectional study analyzed data from the 2017–2020 National Health and Nutrition Examination Survey (NHANES). Weighted multivariate logistic regression models were used to investigate the association between NHR and both MASLD and liver fibrosis. Smoothed curve fitting and threshold effect analysis were performed to detect potential nonlinear relationships. Subgroup analyses were conducted to assess the consistency of these associations across different groups.

Results

The study involved 4,761 participants. We observed a significant positive association between NHR and MASLD (OR = 1.20, 95% CI: 1.09–1.31). However, there was no significant association between NHR and liver fibrosis (OR = 1.01; 95% CI: 0.94–1.09). The analysis of smoothed curve fitting and threshold effect revealed an inverted U-shaped relationship between NHR and MASLD, with a turning point at 5.63.

Conclusion

Our findings indicate a positive correlation between elevated NHR levels and MASLD prevalence. However, we did not observe a significant association between NHR and liver fibrosis prevalence. Further prospective research is needed to validate these findings in a longitudinal setting.

Keywords

Ratio of neutrophils-to-high-density lipoprotein cholesterol
NHANES
Metabolic dysfunction-associated steatotic liver disease
MASLD
Liver fibrosis
Cross-sectional study
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide [1]. This intricate disease is a metabolic-related disease influenced by a range of factors, including genetic, lifestyle, and socioeconomic aspects [2]. The worldwide prevalence of MASLD ranges approximately between 13% and 42%, with increasing incidence attributed to high-energy diets and lack of physical activity [3, 4]. MASLD is characterized by the accumulation of extra fat in the liver, no history of heavy drinking, or only a small amount of alcohol, and is often associated with metabolic disorders such as insulin resistance, type 2 diabetes, and obesity [5–7]. Disease-destructive evolution includes stages of steatosis, metabolic dysfunction-associated steatohepatitis (MASH), severe liver fibrosis, and cirrhosis [8]. The latter stages, particularly liver fibrosis and cirrhosis, may lead to permanent structural alterations and potentially hepatocellular carcinoma (HCC) [9–11]. Due to its increasing incidence, MASLD has become a leading cause of hepatocellular cancer, cirrhosis, fibrosis, and even liver transplantation [12], imposing a heavy financial burden on individuals and society. Therefore, identifying effective, rapid, and affordable biomarkers is crucial for the early identification of individuals at high risk of MASLD.

Neutrophils, as early participants in the inflammatory response, can initiate and regulate inflammation and cellular damage during the progression of MASLD by engulfing lipids and producing inflammatory cytokines and oxygen radicals [13]. High-density lipoprotein cholesterol (HDL-C) possesses anti-inflammatory and antioxidative properties. Additionally, it helps the body eliminate dietary cholesterol through the reverse cholesterol transport mechanism [14]. Lower HDL-C levels are associated with MASLD incidence and severity [15]. The neutrophil-to-HDL-C ratio (NHR) serves as one of the biomarkers for assessing the state of inflammation and lipid metabolism, determined by calculating the ratio between neutrophil count and levels of high-density lipoprotein cholesterol [16]. Elevated NHR value is generally considered as an indicator of chronic inflammation and lipid metabolism disorder [17]. Previous studies have linked NHR with several disorders, such as coronary heart disease [18], diabetes [19], mental illness [20], and Parkinson’s disease [21]. Moreover, it has been demonstrated that NHR may be a useful predictive factor of mortality for liver cancer patients [22]. Despite these associations, research on the correlation between NHR and MASLD remains limited.

To establish a clinically available monitoring index for predicting MASLD risk, we, conducted a representative cross-sectional study using data from the National Health and Nutrition Survey (NHANES) 2017–2020. This study aimed to investigate the correlation between NHR and MASLD as well as liver fibrosis in the general population of the United States.

Patients and methods

Data and sample source

NHANES is a population-representative survey conducted in the United States, employing sophisticated multi-stage and probabilistic sampling to provide comprehensive data on the dietary habits and overall health of the US populace [23]. This analysis utilized continuous NHANES data from the 2017 to 2020 cycles, involving 15,560 participants. Participants were excluded based on the following criteria: lack of necessary data to calculate NHR (n = 4742), missing data on median stiffness/CAP or incomplete elastography (n = 2455), information on heavy drinking data (defined as male average daily drinking > 30 g, female average daily drinking > 20 g) [24] or missing data on drinking (n = 1304), missing data on other underlying liver disease causes (n = 159), including autoimmune hepatitis, viral hepatitis infection (defined as HCV-RNA, HCV antibody, or HBsAg test positive), liver cancer, and missing data on covariates (n = 2258). Ultimately, 4,761 individuals were included in the study (Fig. 1).

Fig. 1 Flowchart of the sample selection. NHANES, National Health and Nutrition Examination Survey. NHR, Ratio of neutrophils to high-density lipoprotein cholesterol. CAP, Controlled Attenuation Parameter

Evaluation of hepatic steatosis and hepatic fibrosis

During the 2017–2020 cycle, NHANES technicians performed vibration-controlled transient elastography (VCTE) using FibroScan ® model 502 V2 Touch (Echosens) with medium (M) and super large (XL) probes. An influential study has identified that the CAP value (also known as CAP) ≥ 274dB/m, ≥ 290dB/m, and ≥ 302dB/m correspond to hepatic steatosis grades S1, S2, and S3, respectively, with a 90% sensitivity in identifying these conditions [25]. Liver fibrosis stages are determined based on liver stiffness, with threshold values for fibrosis stages ≥ F2, ≥F3, and F4 being 8.2, 9.7, and 13.6 kPa, respectively [25, 26].

Definition of MASLD and liver fibrosis

The definition of MASLD is based on hepatic steatosis(≥ S1), the absence of heavy alcohol consumption, and no viral hepatitis, along with meeting at least one of the following conditions [24, 27]: (1) Individuals with a BMI ≥ 25 kg/m2 or a waist circumference ≥ 94 cm for men and ≥ 80 cm for women; (2) Fasting glucose levels ≥ 100 mg/dL or hemoglobin A1c levels ≥ 5.7%, or a history of type 2 diabetes diagnosis or current treatment for type 2 diabetes; (3) Blood pressure levels ≥ 130/85 mmHg or current treatment for hypertension; (4) Triglyceride levels ≥ 1.70 mmol/L or individuals on lipid-lowering therapy; (5) Low high-density lipoprotein cholesterol levels, with < 1.0 mmol/L for men or those on lipid-lowering therapy, and < 1.3 mmol/L for women. Clinically significant fibrosis is defined by LSM thresholds ≥ 8.2 kPa. MASLD and liver fibrosis are the primary outcomes of this study.

Calculation of NHR

Neutrophil counts were determined by total blood count using an automated blood analysis system (Coulter DxH 800 analyzer) and displayed as 10 ^ 3 cells / µ l. HDL-C levels were assessed using an automatic device with venous blood samples obtained after 8-hour fasting. The Neutrophil to High-Density Lipoprotein Cholesterol Ratio (NHR) is calculated as the neutrophil count (10^3 cells/µL) divided by the HDL-C level (mmol/L) [28, 29]. The standard reference range for HDL-C is 1.3–1.5 mmol/L for females and 1.0–1.5 mmol/L for males. Similarly, the range for neutrophil counts is 1.5–8.0 × 10^3 cells /uL.

Covariates

These covariates considered in this study included age (years), sex (male/female), ethnicity (Mexican American/other Hispanic/non-Hispanic White/non-Hispanic Black/other race), education (below grade 9/grades 9–11 (including grade 12), no diploma)/high school graduation or GED or equivalent/some college or AA degrees and college degree or above), and Income-to-Poverty Ratio (PIR). Additionally, smoking status (never/before/now), body mass index (BMI, kg/m2), sedentary behavior (hour/day), Hypertension (yes/no), Diabetes Grade (Normal/Diabetes/Prediabetes), Alanine aminotransferase (ALT, IU/L), HbA1c (HbA1c, %), serum albumin (ALB, g/dL), serum creatinine (SCr, umol/L), total cholesterol (mmol/L), and serum uric acid (µmol/L) were considered. PIR categories were defined as < 1, 1-3.9, and 4, representing low, middle, and high-income groups, respectively. In this research, BMI categories of < 25, 25–29.9, and 30 kg/m2 corresponded to normal weight, overweight, and obese populations, respectively. For comprehensive measurement instructions on these variables, please visit the NHANES website at www.cdc.gov/nchs/nhanes/.

Statistical analysis

Versions 4.2 and 4.1 of Empowerstats and R were used for all the analyses. Weighting was done following NCHS analytical criteria, and then all data were statistically examined. Continuous variables were presented as means ± standard error, and categorical variables were expressed as values and percentages. Weighted chi-square tests and t-tests were used for categorical and continuous variables, respectively. Utilizing weighted logistics regression analysis, we examined the association between independent and dependent variables. Based on covariate adjustments, three models were developed. Model 1: Unadjusted covariates. Model 2: Adjusted for PIR, age, sex, race, and education. Model 3: Building upon Model 2, further adjusted for uric acid, albumin, creatinine, ALT, hemoglobin A1c, BMI, sedentary behavior, hypertension, diabetes, and cholesterol. The linear and nonlinear relations between NHR and NAFLD are studied by fit-smoothed curves. Subgroup analyses were conducted based on gender, ethnicity, BMI, hypertension, and diabetes status. Statistical significance was set at a two-sided P < 0.05.

Results

Baseline characteristics

A total of 4,761 participants were included in this study, with 2,123 (44.08%) being found with MASLD and 453 (8.82%) exhibiting liver fibrosis. All participants were aged over 20, with a mean age of 48.22 ± 17.15 years. The sample consisted of 48.45% male and 51.55%female. The ranges of NHR across quartiles 1–4 were as follows: Q1(0.191–2.065), Q2(2.067–2.993), Q3(3.000-4.207) and Q4(4.211–19.028). In the NHR quartile(Q1 to Q4), significant differences were observed in age, gender, race, education level, PIR, smoking, sedentary, BMI, hypertension, diabetes grade, hemoglobin A1c, ALT, serum albumin, serum creatinine, total cholesterol, and serum uric acid (all P < 0.05). Male, non-Hispanic White, below college degree, moderately income, longer periods of sedentary behavior, elevated BMI, hypertension, diabetes, elevated HbA1c levels, elevated levels of creatinine, uric acid, and ALT in the blood serum, and a history of smoking were all associated with higher levels of NHR. Conversely, lower levels of albumin and cholesterol in the blood serum were linked to higher levels of NHR (Table 1).

Table 1 Clinical characteristics of the study participants

NHR	Total	Q1	Q2	Q3	Q4	P-value	
Sample size	4761	1186	1190	1191	1194		
Age(years)	48.22 ± 17.15	49.81 ± 17.23	48.42 ± 17.22	47.67 ± 17.36	47.66 ± 16.86	0.0091	
Sex, n(%)						< 0.0001	
Male	2267(48.45%)	426(34.96%)	548(46.68%)	601(50.91%)	692(59.24%)		
Female	2497(51.55%)	760(65.04%)	642(53.32%)	590(49.09%)	502(40.76%)		
Race, n(%)						< 0.0001	
Mexican American	574(8.35%)	83(5.29%)	151(8.38%)	151(8.52%)	189(10.78%)		
Other Hispanic	481(7.09%)	94(5.88%)	104(6.24%)	152(8.46%)	131(7.54%)		
Non-Hispanic White	1733(64.58%)	320(58.87%)	427(64.69%)	467(67.27%)	519(66.56%)		
Non-Hispanic Black	1185(10.56%)	484(20.10%)	315(11.23%)	226(7.41%)	161(4.98%)		
Other Race - Including Multi-Racial	788(9.42%)	205(9.86%)	194(9.46%)	195(8.33%)	194(10.13%)		
Education level, n(%)						< 0.0001	
Less than 9th grade	306(3.00%)	51(2.12%)	76(2.61%)	83(2.99%)	96(4.17%)		
9-11th grade (Includes 12th grade with no diploma)	497(6.91%)	89(4.00%)	128(7.38%)	128(7.33%)	152(8.53%)		
High school graduate/GED or equivalent	1117(26.50%)	252(19.83%)	241(20.92%)	303(31.32%)	321(32.69%)		
Some college or AA degree	1623(31.74%)	395(30.51%)	402(31.06%)	419(30.03%)	407(34.20%)		
College graduate or above	1218(31.85%)	399(43.54%)	343(38.03%)	258(27.33%)	218(20.42%)		
PIR, n(%)						< 0.0001	
Low income(< 1)	862(11.87%)	210(10.85%)	178(8.98%)	236(13.51%)	238(13.86%)		
Median income(1-3.9)	2585(48.37%)	606(43.96%)	659(49.06%)	625(45.80%)	695(54.17%)		
High income(≥ 4)	1314(39.76%)	370(45.19%)	353(41.96%)	330(40.69%)	261(31.97%)		
Smoking, n(%)						< 0.0001	
Never	2883(60.67%)	818(68.73%)	749(65.08%)	706(59.26%)	610(51.47%)		
Ever	1136(25.46%)	246(22.84%)	287(24.88%)	288(26.06%)	315(27.13%)		
Now	742(13.87%)	122(8.44%)	154(10.04%)	197(14.68%)	269(21.40%)		
Sedentary(h/day), n(%)						0.0002	
<6	2712(52.31%)	714(55.73%)	680(50.24%)	685(55.11%)	633(48.35%)		
≥ 6	2049(47.69%)	472(44.27%)	510(49.76%)	506(44.89%)	561(51.65%)		
BMI(kg/m²),n(%)						< 0.0001	
<25	1159(24.61%)	468(45.83%)	318(25.88%)	241(19.66%)	132(10.25%)		
25-29.9	1561(32.54%)	401(33.25%)	418(37.27%)	388(20.11%)	354(29.80%)		
≥ 30	2041(42.86%)	317(21.92%)	454(36.85%)	562(50.23%)	708(59.95%)		
Hypertension, n (%)						< 0.0001	
NO	2652(61.42%)	710(67.59%)	680(67.42%)	663(60.60%)	599(50.64%)		
Yes	2109(38.58%)	476(32.41%)	510(32.58%)	528(38.40%)	595(49.36%)		
Diabetes Grade, n (%)						< 0.0001	
Normal	3377(76.69%)	942((85.01%)	854(79.75%)	840(76.28%)	741(66.94%)		
Diabetes	972(15.61%)	134(6.86%)	214(11.15%)	252(16.55%)	372(26.53%)		
Prediabetes	412(7.71%)	1110(8.13%)	122(9.11%)	99(7.17%)	81(6.52%)		
HbA1c (%)	5.68 ± 0.97	5.49 ± 0.65	5.60 ± 0.79	5.72 ± 0.95	6.02 ± 1.34	< 0.0001	
ALT(IU/L)	22.27 ± 14.90	18.72 ± 10.06	21.01 ± 12.94	22.92 ± 15.48	25.77 ± 18.36	< 0.0001	
ALB(g/L)	41.17 ± 3.14	41.26 ± 3.15	41.46 ± 3.05	41.15 ± 3.16	40.83 ± 3.17	< 0.0001	
SCr (umol/L)	77.88 ± 33.62	74.19 ± 19.03	77.50 ± 30.39	79.44 ± 46.78	79.83 ± 29.49	0.0002	
Total Cholesterol(mmol/L)	4.85 ± 1.04	5.02 ± 1.03	4.81 ± 1.00	4.79 ± 0.99	4.81 ± 1.11	< 0.0001	
Serum Uric acid (umol/L)	316.23 ± 82.96	291.67 ± 77.53	308.62 ± 77.63	320.54 ± 82.57	340.48 ± 85.81	< 0.0001	
MASLD, n (%)						< 0.0001	
NO	2638(55.92%)	870(76.68%)	722(62.84%)	597(50.75%)	499(36.64%)		
Yes	2123(44.08%)	316(23.32%)	468(37.16%)	594(59.25%)	745(63.36%)		
Hepatic fibrosis, n (%)						< 0.0001	
NO	4308(91.18%)	1126(96.37%)	1103(94.49%)	1064(90.01%)	1015(84.66%)		
Yes	453(8.82%)	60(3.63%)	87(5.51%)	127(9.99%)	179(15.34%)		
Mean ± SD for continuous variables: the P value was calculated by the weighted linear regression model. (%) for categorical variables: the P value was calculated by the weighted chi-square test

HDL-C, High-density lipoprotein cholesterol; PIR, Income-to-Poverty Ratio; BMI, body mass index; HbA1c (%), glycated hemoglobin; ALT, alanine transaminase; SCr, serum creatinine; ALB, serum albumin; CAP, Controlled Attenuation Parameter; LSM, liver stiffness measure; NHR, Ratio of neutrophils-to-high-density lipoprotein cholesterol

Association between NHR and MASLD

The outcomes of the logistic regression models for the three models are presented in Table 2. NHR and MASLD showed a significant positive correlation in both the unadjusted model (Model 1: OR = 1.48, 95% CI: 1.38–1.56) and the model adjusted for age, sex, race, education level, and PIR (Model 2: OR = 1.49, 95% CI: 1.37–1.62). The positive association between NHR and NAFLD remained significant (Model 3:OR = 1.20, 95% CI: 1.09–1.31) even after adjusting for all variables. Upon stratifying the data by NHR quartiles, we found that Q4 continued to exhibit a significantly positive correlation with MASLD, even after accounting for all other factors (Model 3: OR = 3.00, 95%CI: 2.10–4.30). Using Q1 as a reference, each unit increase in the NHR ratio was associated with a 3-fold increase in the odds of MASLD prevalence.

Table 2 Association between NHR and MASLD

Model	Model 1
OR (95% CI)	Model 2
OR (95% CI)	Model 3
OR (95% CI)	
NHR(continuous)	1.48(1.38, 1.56)	1.49 (1.37, 1.62)	1.20(1.09, 1.31)	
NHR (quartile)				
Q1(0.231–2.022)	Ref	Ref	Ref	
Q2(2.023–2.948)	2.25 (1.77, 2.87)	2.38 (1.83, 3.10)	1.71 (1.21, 2.41)	
Q3(2.951–4.172)	3.38 (2.66, 4.27)	3.66 (2.84, 4.72)	1.87 (1.40, 2.50)	
Q4(4.173–16.769)	6.99 (5.55, 8.81)	7.58 (5.85, 9.83)	3.00 (2.10, 4.30)	
Model 1: no covariates were adjusted

Model 2: adjusted for age, race, education, sex, PIR

Model 3: adjusted for age, race, education, sex, PIR, BMI, diabetes grade, hypertension, smoking, sedentary, total cholesterol, ALT, HbA1c (%), ALB, SCr, serum uric acid

95% CI: 95% confidence interval

Association between NHR and liver fibrosis

Table 3 presents the results of logistic regression models, showing that in Model 1 (OR = 1.24, 95% CI: 1.16–1.32) and Model 2 (OR = 1.22, 95% CI: 1.14–1.30), there is a significant positive association between NHR and liver fibrosis. However, the positive association between NHR and liver fibrosis becomes non-significant after adjusting for all variables (Model 3:OR = 1.01; 95% CI: 0.94–1.09). When examining NHR quartiles, Q3 and Q4 exhibit a significantly positive correlation with liver fibrosis in Models 1 (Q3: OR = 2.29, 95% CI: 1.64–3.19; Q4: OR = 3.41, 95% CI: 2.46–4.73)and 2(Q3:OR = 2.06, 95% CI: 1.39–3.06; Q4: OR = 2.96, 95% CI: 1.97–4.46). However, in Model 3, there is no statistically significant association between Q3 (OR = 0.98, 95% CI: 0.64–1.52) and Q4 (OR = 0.97, 95% CI: 0.60–1.55) and hepatic fibrosis.

Table 3 Association between NHR and liver fibrosis

Model	Model 1
OR (95% CI)	Model 2
OR (95% CI)	Model 3
OR (95% CI)	
NHR(continuous)	1.24 (1.16,1.32)	1.22 (1.14,1.30)	1.01 (0.94, 1.09)	
NHR (quartile)				
Q1(0.231–2.022)				
Q2(2.023–2.948)	1.28 (0.90, 1.82)	1.24 (0.85, 1.80)	0.76 (0.49, 1.19)	
Q3(2.951–4.172)	2.29 (1.64, 3.19)	2.06 (1.39, 3.06)	0.98 (0.64, 1.52)	
Q4(4.173–16.769)	3.41 (2.46, 4.73)	2.96 (1.97, 4.46)	0.97 (0.60, 1.55)	
Model 1: no covariates were adjusted

Model 2: adjusted for age, race, education, sex, PIR

Model 3: adjusted for age, race, education, sex, PIR, BMI, diabetes grade, hypertension, smoking, Sedentary, Total cholesterol, ALT, HbA1c (%), ALB, SCr, serum uric acid

95% CI: 95% confidence interval

Smoothing curve fitting and threshold effect analysis

After adjusting for each variable, an inverted U-shaped relationship between NHR and MASLD was observed (Fig. 2A). However, there was a positive correlation between NHR and liver fibrosis (Fig. 2B). The inflection point of the inverted U-shaped relationship between NHR and MASLD was determined to be 5.63. For NHR > 5.63, there was a negative correlation with MASLD (OR = 0.86,95% CI: 0.76–0.97), whereas for NHR < 5.63, a positive correlation was observed (OR = 1.35,95% CI: 1.27–1.45). However, there was no significant positive correlation between NHR and liver fibrosis (OR = 1.01,95% CI: 0.94–1.09) (Table 4).

Fig. 2 Smooth-curve fitting of NHR, MASLD, and liver fibrosis. (A) The association between NHR and MASLD. (B) The association between NHR and liver fibrosis. The solid red line represents the smooth curve fit between variables. Blue bands represent the 95% confidence interval from the fit. All the covariates in Table 1 are adjusted

Table 4 Threshold effect of the relationship between NHR, MASLD, and liver fibrosis

Outcomes	NAFLD	Liver fibrosis	
Model 1, OR (95% CI)			
Linear effect model	1.20(1.09, 1.31)	1.01 (0.94, 1.09)	
Model 2, OR(95% CI)			
Inflection point (K)	5.63	1.74	
< K	1.35 (1.27, 1.45)	0.79 (0.40, 1.56)	
> K	0.86 (0.76, 0.97)	1.06 (0.97, 1.10)	
LLR	< 0.001	0.424	
LLR, Log likelihood ratio. 95% CI, 95% confidence interval

Subgroup analysis

Subgroup analysis revealed inconsistent correlations between the NHR level, MASLD, and hepatic fibrosis. Across subgroups stratified by sex, BMI, and hypertension, a substantial positive association between NHR and MASLD was observed (all P < 0.05), as shown in Table 5. Similarly, significant positive correlations (P < 0.05) were found among Mexican Americans, non-Hispanic Whites, non-Hispanic Blacks, and other racial groups in ethnic stratification. However, no significant correlation between NHR and MASLD was observed among individuals with prediabetes. The correlation between NHR and MASLD did not change significantly throughout subgroups, according to the interaction test (P for interaction > 0.05). The subgroup analysis of the correlation between NHR and liver fibrosis shows that in each subgroup based on sex and hypertension, there is a positive correlation between NHR and liver fibrosis, although it is not statistically significant (P > 0.05). Notably, in subgroups based on race, BMI, and diabetes, Only Mexican Americans, other races, BMI > 30(kg/m²) and Diabetes show a statistically significant positive correlation between NHR and liver fibrosis (P < 0.05). According to interaction testing, there is no significant difference in the correlation between NHR and liver fibrosis across these subgroups (P for interaction > 0.05) (Table 6).

Table 5 Subgroup of the relationship between NHR and MASLD

Subgroup	OR (95%CI)	P for interaction	
Sex		0.2065	
Male	1.16(1.09,1.25)		
Female	1.24(1.15,1.33)		
Race		0.1089	
Mexican American	1.26(1.08,1.48)		
Other Hispanic	1.05(0.91,1.22)		
Non-Hispanic White	1.25(1.15,1.37)		
Non-Hispanic Black	1.12(1.01,1.24)		
Other Race	1.30(1.14,1.48)		
BMI(kg/m²)		0.5208	
< 25	1.28(1.13,1.45)		
25-29.9	1.17(1.09,1.26)		
> 30	1.21(1.11,1.31)		
Hypertension		0.8820	
Yes	1.20(1.11,1.30)		
NO	1.19(1.12,1.27)		
Diabetes Grade		0.3913	
Diabetes	1.13 (1.01,1.26)		
Prediabetes	1.08 (0.91, 1.27)		
Normal	1.17 (1.11, 1.24)		

Table 6 Subgroup of the relationship between NHR and liver fibrosis

Subgroup	OR (95%CI)	P for interaction	
Sex		0.4170	
Male	1.03(0.95,1.11)		
Female	1.08(0.99,1.18)		
Race		0.0637	
Mexican American	1.22(1.00,1.47)		
Other Hispanic	1.16(0.95,1.44)		
Non-Hispanic White	0.99 (0.90, 1.09)		
Non-Hispanic Black	1.00(0.87,1.14)		
Other Race	1.22(1.04,1.43)		
BMI(kg/m²)		0.1576	
< 25	0.80(0.63,1.03)		
25-29.9	1.03(0.90,1.18)		
> 30	1.07(1.01,1.15)		
Hypertension		0.6111	
Yes	1.06(0.99,1.14)		
NO	1.03(0.93,1.14)		
Diabetes Grade		0.069	
Diabetes	1.11(1.02,1.20)		
Prediabetes	0.99(0.92,1.08)		
Normal	0.89(0.75,1.09)		

Discussion

In this cross-sectional study involving 4,761 participants, we identified a positive correlation between NHR levels and MASLD. However, no significant positive association was observed between liver fibrosis and NHR levels. Subgroup analyses and interaction tests indicated that this relationship is consistent across various populations. It is noteworthy that the association between NHR and MASLD exhibits an inverted U-shaped pattern, with an inflection point at 5.63. Below this threshold, NHR was identified as an independent risk factor for MASLD.

Currently, there are limited investigations on the relationship between NHR and MASLD, and only one study reported an association [29]. Enver and his colleagues examined the connection between NHR and MASLD among 155 Turkish participants. Using one-way ANOVA for multiple comparisons, they found that NHR levels were higher in individuals with moderate and severe liver fat degeneration compared to those without liver fat degeneration [29]. However, this study was limited by its relatively small sample size and did not comprehensively assess the impact of other risk factors on the association between NHR and MASLD.

Currently, many epidemiological studies have proved that inflammatory reaction and lipid metabolism are related to the progress of MASLD [30–33]. The advanced stage of MASLD, known as MASH, is characterized by hepatocyte fibrosis and inflammation in addition to fat buildup [34]. A large multicenter cohort study involving 389 MASLD patients with significant liver fibrosis from Finland and Italy found that one-third of patients with severe fibrosis in biopsy samples did not exhibit NASH [35]. Our study revealed a lack of significant correlation between NHR and hepatic fibrosis, which may explain this phenomenon. In a cross-sectional investigation of MASLD in the US population, Xie and his colleagues similarly found no discernible relationship between liver fibrosis and the systemic immune inflammation index, consistent with our findings [36]. These results may suggest that the complex process of liver fibrosis can not be fully reflected by the assessment of the inflammatory response alone. Liver fibrosis is a multifactorial and multistep process, where inflammation is just one component. Other potential mechanisms or factors such as cellular apoptosis [37], oxidative stress [38], and changes in gene expression [39] may also contribute to liver fibrosis, although they were not addressed in our study.

Aberrant infiltration of neutrophils aggravates hepatocyte injury and inflammatory responses by generating reactive oxygen species, releasing proteases, forming neutrophil extracellular traps (NETs), and secreting inflammatory cytokines, thereby driving the MASLD [40]. Studies have shown that myeloperoxidase (MPO) produced by neutrophils can enhance the cytotoxicity of macrophages and induce neutrophil activation in mouse models of MASH [41]. In addition, activated neutrophils exacerbate liver inflammation and damage by releasing inflammatory mediators [40] and enzymes [42], advancing hepatic steatosis to more severe stages of the disease, thus playing a critical role in the pathogenesis of MASH. Another study conducted on animals found that mice treated with the neutrophil-depleting antibody 1A8 significantly reduced the expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and inflammatory cytokines after feeding C57BL/6 J mice a high-fat diet for six weeks [43]. This indicates that the depletion of neutrophils can significantly improve MASLD caused by diet in mice. These findings further validate the potential critical role neutrophils might play in developing MASLD. A negative relationship between HDL-C levels and the risk of MASLD has been demonstrated in numerous research [44, 45]. HDL-C possesses anti-inflammatory and antioxidant effects and can reduce neutrophil activity by inhibiting [46]. Reactive oxygen species and proteases produced by neutrophils can also affect HDL, diminishing its antioxidant and anti-inflammatory capacities [47]. This may partially explain the positive correlation between NHR and MASLD prevalence observed in our study.

NHR, as a novel inflammatory biomarker, integrates the dual consideration of inflammatory status and lipid metabolism. Numerous studies have confirmed that SII(Systemic Immune-Inflammation Index), WWI(weight-adjusted waist index), and CMI (cardiometabolic index) are all associated with MASLD [48–50]. However, NHR stands out in its comprehensiveness compared to these indicators. It not only accurately assesses the state of inflammatory response but also incorporates lipid metabolism into its assessment, a dimension that SII fails to consider. Compared to WWI and CMI, NHR features a simpler calculation process, while the latter two only reflect metabolic status. More importantly, there is a significant positive correlation between NHR and the prevalence of MASLD. Elevated levels of NHR often indicate abnormal inflammatory responses or lipid metabolism, providing an opportunity for early intervention. By timely adjusting NHR levels, we can potentially reduce the risk of MASLD, for example, through measures such as improving lifestyle, to achieve effective disease prevention and control. In other words, NHR is an ideal biomarker for large-scale screening in resource-limited settings due to its simplicity and cost-effectiveness. The laboratory data required for its calculation—neutrophil count and high-density lipoprotein levels—can be easily obtained through routine blood tests without the need for additional specialized tests. As a preliminary screening tool, NHR holds promise in identifying potential high-risk MASLD individuals in the general population, laying the groundwork for more precise diagnostic methods such as abdominal ultrasound, FibroScan, and liver biopsy to confirm hepatic steatosis and facilitate early intervention and treatment.

The results of this study are based on a health survey of the general population, which, although providing valuable information on the prevalence of MASLD, must acknowledge the inherent limitations of the cross-sectional study design. Firstly, due to the cross-sectional design of the study, it is not possible to directly establish a causal relationship between the NHR and the severity of hepatic steatosis. Hence, longitudinal studies and intervention trials are needed to address this limitation. Despite adjusting for numerous confounding variables, it remains challenging to completely exclude all potential biases that could influence our results. Secondly, cross-sectional studies cannot differentiate between various stages of fibrosis or frank cirrhosis, as these diagnoses typically require support from imaging studies such as abdominal ultrasound. Additionally, we are unable to assess the presence or absence of portal hypertension or ascites, conditions commonly seen in cirrhotic patients and significant for disease severity and prognosis. Therefore, further prospective studies are required for further validation in the future. Finally, because a liver biopsy was not used to confirm the diagnosis of MASLD and liver fibrosis made in this study, the current conclusions need to be verified by additional research.

Conclusion

The study results show that an increase in the NHR level is positively correlated with the odds of MASLD prevalence. It is important to note that among participants with an NHR below 5.63, the odds of MASLD prevalence increase as the NHR level rises; however, there is no significant correlation between NHR and the incidence of liver fibrosis. To validate the findings of this study, larger-scale and more meticulously designed prospective studies are needed.

Acknowledgements

We would like to thank all members who contributed to the manuscript.

Author contributions

YL, XX, and HH designed the research. YL, HH, and LJ collected, analyzed the data and drafted the manuscript. MC, XX and JW revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

No funding was obtained for this study.

Data availability

The survey data are publicly available on the internet for data users and researchers throughout the world (www.cdc.gov/nchs/nhanes/).

Declarations

Ethics approval and consent to participate

The portions of this study involving human participants, human materials, or human data were conducted by the Declaration of Helsinki and were approved by the NCHS Ethics Review Board. The patients/participants provided their written informed consent to participate in this study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Abbreviations

NHR Neutrophil-to-high-density lipoprotein cholesterol ratio

MASLD Metabolic dysfunction-associated steatotic liver disease

MASH Metabolic dysfunction-associated steatohepatitis

NHANES National Health and Nutrition Examination Survey

BMI Body mass index

PIR Income-to-Poverty Ratio

HDL-C High-density lipoprotein cholesterol

SII Systemic Immune-Inflammation Index

WWI Weight-adjusted waist index

CMI Cardiometabolic index

ALT Alanine aminotransferase

ALB Albumin

SCr Serum creatinine

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Teng ML Ng CH Huang DQ Chan KE Tan DJ Lim WH Yang JD Tan E Muthiah MD Global incidence and prevalence of nonalcoholic fatty liver disease Clin Mol Hepatol 2023 29 Suppl S32 42 10.3350/cmh.2022.0365 36517002
Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32–42.36517002 10.3350/cmh.2022.0365
2. Aggeletopoulou I, Kalafateli M, Tsounis EP, Triantos C. Epigenetic regulation in lean nonalcoholic fatty liver disease. Int J Mol Sci 2023, 24(16).
3. Dai JJ Zhang YF Zhang ZH Global trends and hotspots of treatment for nonalcoholic fatty liver disease: a bibliometric and visualization analysis (2010–2023) World J Gastroenterol 2023 29 37 5339 60 10.3748/wjg.v29.i37.5339 37899789
Dai JJ, Zhang YF, Zhang ZH. Global trends and hotspots of treatment for nonalcoholic fatty liver disease: a bibliometric and visualization analysis (2010–2023). World J Gastroenterol. 2023;29(37):5339–60.37899789 10.3748/wjg.v29.i37.5339
4. Riazi K Azhari H Charette JH Underwood FE King JA Afshar EE Swain MG Congly SE Kaplan GG Shaheen AA The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis Lancet Gastroenterol Hepatol 2022 7 9 851 61 10.1016/S2468-1253(22)00165-0 35798021
Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61.35798021 10.1016/S2468-1253(22)00165-0
5. Powell EE Wong VW Rinella M Non-alcoholic fatty liver disease Lancet 2021 397 10290 2212 24 10.1016/S0140-6736(20)32511-3 33894145
Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–24.33894145 10.1016/S0140-6736(20)32511-3
6. Syed-Abdul MM. Lipid metabolism in metabolic-Associated Steatotic Liver Disease (MASLD). Metabolites 2023;14(1).
7. Rong L Zou J Ran W Qi X Chen Y Cui H Guo J Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD) Front Endocrinol (Lausanne) 2022 13 1087260 10.3389/fendo.2022.1087260 36726464
Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2022;13:1087260.36726464 10.3389/fendo.2022.1087260
8. Thomas JA Kendall BJ El-Serag HB Thrift AP Macdonald GA Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease Lancet Gastroenterol Hepatol 2024 9 2 159 69 10.1016/S2468-1253(23)00275-3 38215780
Thomas JA, Kendall BJ, El-Serag HB, Thrift AP, Macdonald GA. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2024;9(2):159–69.38215780 10.1016/S2468-1253(23)00275-3
9. Sheka AC Adeyi O Thompson J Hameed B Crawford PA Ikramuddin S Nonalcoholic steatohepatitis: a review JAMA 2020 323 12 1175 83 10.1001/jama.2020.2298 32207804
Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175–83.32207804 10.1001/jama.2020.2298
10. Schuppan D Schattenberg JM Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches J Gastroenterol Hepatol 2013 28 Suppl 1 68 76 10.1111/jgh.12212 23855299
Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28(Suppl 1):68–76.23855299 10.1111/jgh.12212
11. Kim GA, Lee HC, Choe J, Kim MJ, Lee MJ, Chang HS, Bae IY, Kim HK, An J, Shim JH et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol 2017.
12. Streba LA Vere CC Rogoveanu I Streba CT Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question World J Gastroenterol 2015 21 14 4103 10 10.3748/wjg.v21.i14.4103 25892859
Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol. 2015;21(14):4103–10.25892859 10.3748/wjg.v21.i14.4103
13. Nati M Haddad D Birkenfeld AL Koch CA Chavakis T Chatzigeorgiou A The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH) Rev Endocr Metab Disord 2016 17 1 29 39 10.1007/s11154-016-9339-2 26847547
Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T, Chatzigeorgiou A. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev Endocr Metab Disord. 2016;17(1):29–39.26847547 10.1007/s11154-016-9339-2
14. Kou T Luo H Yin L Relationship between neutrophils to HDL-C ratio and severity of coronary stenosis BMC Cardiovasc Disord 2021 21 1 127 10.1186/s12872-020-01771-z 33676400
Kou T, Luo H, Yin L. Relationship between neutrophils to HDL-C ratio and severity of coronary stenosis. BMC Cardiovasc Disord. 2021;21(1):127.33676400 10.1186/s12872-020-01771-z
15. Corey KE Chalasani N Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 2014 12 7 1077 84 10.1016/j.cgh.2013.08.014 23962548
Corey KE, Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(7):1077–84. quiz e1059-1060.23962548 10.1016/j.cgh.2013.08.014
16. Guo J Chen M Hong Y Huang Y Zhang H Zhou Y Zhou B Fu M Comparison of the Predicting Value of Neutrophil to high-density Lipoprotein Cholesterol Ratio and Monocyte to high-density lipoprotein cholesterol ratio for in-hospital prognosis and severe coronary artery stenosis in patients with ST-Segment Elevation Acute Myocardial Infarction following percutaneous coronary intervention: a retrospective study J Inflamm Res 2023 16 4541 57 10.2147/JIR.S425663 37868828
Guo J, Chen M, Hong Y, Huang Y, Zhang H, Zhou Y, Zhou B, Fu M. Comparison of the Predicting Value of Neutrophil to high-density Lipoprotein Cholesterol Ratio and Monocyte to high-density lipoprotein cholesterol ratio for in-hospital prognosis and severe coronary artery stenosis in patients with ST-Segment Elevation Acute Myocardial Infarction following percutaneous coronary intervention: a retrospective study. J Inflamm Res. 2023;16:4541–57.37868828 10.2147/JIR.S425663
17. Chen Y Jiang D Tao H Ge P Duan Q Neutrophils to high-density lipoprotein cholesterol ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a retrospective study BMC Cardiovasc Disord 2022 22 1 434 10.1186/s12872-022-02870-9 36199038
Chen Y, Jiang D, Tao H, Ge P, Duan Q. Neutrophils to high-density lipoprotein cholesterol ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord. 2022;22(1):434.36199038 10.1186/s12872-022-02870-9
18. Gao J Lu J Sha W Xu B Zhang C Wang H Xia J Zhang H Tang W Lei T Relationship between the neutrophil to high-density lipoprotein cholesterol ratio and severity of coronary artery disease in patients with stable coronary artery disease Front Cardiovasc Med 2022 9 1015398 10.3389/fcvm.2022.1015398 36505389
Gao J, Lu J, Sha W, Xu B, Zhang C, Wang H, Xia J, Zhang H, Tang W, Lei T. Relationship between the neutrophil to high-density lipoprotein cholesterol ratio and severity of coronary artery disease in patients with stable coronary artery disease. Front Cardiovasc Med. 2022;9:1015398.36505389 10.3389/fcvm.2022.1015398
19. Song Y Zhao Y Shu Y Zhang L Cheng W Wang L Shu M Xue B Wang R Feng Z Combination model of neutrophil to high-density lipoprotein ratio and system inflammation response index is more valuable for predicting peripheral arterial disease in type 2 diabetic patients: a cross-sectional study Front Endocrinol (Lausanne) 2023 14 1100453 10.3389/fendo.2023.1100453 36875480
Song Y, Zhao Y, Shu Y, Zhang L, Cheng W, Wang L, Shu M, Xue B, Wang R, Feng Z, et al. Combination model of neutrophil to high-density lipoprotein ratio and system inflammation response index is more valuable for predicting peripheral arterial disease in type 2 diabetic patients: a cross-sectional study. Front Endocrinol (Lausanne). 2023;14:1100453.36875480 10.3389/fendo.2023.1100453
20. Wei Y Wang T Li G Feng J Deng L Xu H Yin L Ma J Chen D Chen J Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder Front Psychiatry 2022 13 941728 10.3389/fpsyt.2022.941728 35958647
Wei Y, Wang T, Li G, Feng J, Deng L, Xu H, Yin L, Ma J, Chen D, Chen J. Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder. Front Psychiatry. 2022;13:941728.35958647 10.3389/fpsyt.2022.941728
21. Liu Z Fan Q Wu S Wan Y Lei Y Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson’s disease Lipids Health Dis 2021 20 1 35 10.1186/s12944-021-01462-4 33874966
Liu Z, Fan Q, Wu S, Wan Y, Lei Y. Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson’s disease. Lipids Health Dis. 2021;20(1):35.33874966 10.1186/s12944-021-01462-4
22. Shi K Hou J Zhang Q Bi Y Zeng X Wang X Neutrophil-to-high-density-lipoprotein-cholesterol ratio and mortality among patients with hepatocellular carcinoma Front Nutr 2023 10 1127913 10.3389/fnut.2023.1127913 37215223
Shi K, Hou J, Zhang Q, Bi Y, Zeng X, Wang X. Neutrophil-to-high-density-lipoprotein-cholesterol ratio and mortality among patients with hepatocellular carcinoma. Front Nutr. 2023;10:1127913.37215223 10.3389/fnut.2023.1127913
23. Akinbami LJ, Chen TC, Davy O, Ogden CL, Fink S, Clark J, Riddles MK, Mohadjer LK. National Health and Nutrition Examination Survey, 2017-March 2020 Prepandemic file: Sample Design, Estimation, and Analytic guidelines. Vital Health Stat 1 2022(190):1–36.
24. EASL-EASD-EASO Clinical. Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia 2024.
25. Eddowes PJ Sasso M Allison M Tsochatzis E Anstee QM Sheridan D Guha IN Cobbold JF Deeks JJ Paradis V Accuracy of FibroScan Controlled Attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease Gastroenterology 2019 156 6 1717 30 10.1053/j.gastro.2019.01.042 30689971
Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, et al. Accuracy of FibroScan Controlled Attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30.30689971 10.1053/j.gastro.2019.01.042
26. Ciardullo S Perseghin G Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes Metabolism 2021 121 154752 10.1016/j.metabol.2021.154752 33716004
Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism. 2021;121:154752.33716004 10.1016/j.metabol.2021.154752
27. Rinella ME Lazarus JV Ratziu V Francque SM Sanyal AJ Kanwal F Romero D Abdelmalek MF Anstee QM Arab JP A multisociety Delphi consensus statement on new fatty liver disease nomenclature J Hepatol 2023 79 6 1542 56 10.1016/j.jhep.2023.06.003 37364790
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–56.37364790 10.1016/j.jhep.2023.06.003
28. Lamichhane P Agrawal A Abouainain Y Abousahle S Regmi PR Utility of neutrophil-to-high-density lipoprotein-cholesterol ratio in patients with coronary artery disease: a narrative review J Int Med Res 2023 51 4 3000605231166518 10.1177/03000605231166518 37038922
Lamichhane P, Agrawal A, Abouainain Y, Abousahle S, Regmi PR. Utility of neutrophil-to-high-density lipoprotein-cholesterol ratio in patients with coronary artery disease: a narrative review. J Int Med Res. 2023;51(4):3000605231166518.37038922 10.1177/03000605231166518
29. Huang JB Chen YS Ji HY Xie WM Jiang J Ran LS Zhang CT Quan XQ Neutrophil to high-density lipoprotein ratio has a superior prognostic value in elderly patients with acute myocardial infarction: a comparison study Lipids Health Dis 2020 19 1 59 10.1186/s12944-020-01238-2 32247314
Huang JB, Chen YS, Ji HY, Xie WM, Jiang J, Ran LS, Zhang CT, Quan XQ. Neutrophil to high-density lipoprotein ratio has a superior prognostic value in elderly patients with acute myocardial infarction: a comparison study. Lipids Health Dis. 2020;19(1):59.32247314 10.1186/s12944-020-01238-2
30. Avcı E, Ozturk M. Evaluation of neutrophil HDL-C ratio - a new inflammation marker in non-alcoholic fatty liver disease. Endokrynol Pol 2023, 74(6).
31. Pei K, Gui T, Kan D, Feng H, Jin Y, Yang Y, Zhang Q, Du Z, Gai Z, Wu J et al. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. Biomed Res Int 2020, 2020:4020249.
32. Ruan S Han C Sheng Y Wang J Zhou X Guan Q Li W Zhang C Yang Y Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3 Int Immunopharmacol 2021 100 108126 10.1016/j.intimp.2021.108126 34492534
Ruan S, Han C, Sheng Y, Wang J, Zhou X, Guan Q, Li W, Zhang C, Yang Y. Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3. Int Immunopharmacol. 2021;100:108126.34492534 10.1016/j.intimp.2021.108126
33. Zhang B Lu J Jiang Y Feng Y Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling Immun Inflamm Dis 2023 11 8 e947 10.1002/iid3.947 37647445
Zhang B, Lu J, Jiang Y, Feng Y. Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling. Immun Inflamm Dis. 2023;11(8):e947.37647445 10.1002/iid3.947
34. Pelusi S Cespiati A Rametta R Pennisi G Mannisto V Rosso C Baselli G Dongiovanni P Fracanzani AL Badiali S Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without Steatohepatitis Clin Gastroenterol Hepatol 2019 17 11 2310 e23192316 10.1016/j.cgh.2019.01.027 30708111
Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, et al. Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without Steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(11):2310–e23192316.30708111 10.1016/j.cgh.2019.01.027
35. Ore A, Akinloye OA. Oxidative stress and antioxidant biomarkers in clinical and experimental models of non-alcoholic fatty liver disease. Med (Kaunas) 2019, 55(2).
36. Xie R Xiao M Li L Ma N Liu M Huang X Liu Q Zhang Y Association between SII and hepatic steatosis and liver fibrosis: a population-based study Front Immunol 2022 13 925690 10.3389/fimmu.2022.925690 36189280
Xie R, Xiao M, Li L, Ma N, Liu M, Huang X, Liu Q, Zhang Y. Association between SII and hepatic steatosis and liver fibrosis: a population-based study. Front Immunol. 2022;13:925690.36189280 10.3389/fimmu.2022.925690
37. Su Y Lu S Hou C Ren K Wang M Liu X Zhao S Liu X Mitigation of liver fibrosis via hepatic stellate cells mitochondrial apoptosis induced by metformin Int Immunopharmacol 2022 108 108683 10.1016/j.intimp.2022.108683 35344814
Su Y, Lu S, Hou C, Ren K, Wang M, Liu X, Zhao S, Liu X. Mitigation of liver fibrosis via hepatic stellate cells mitochondrial apoptosis induced by metformin. Int Immunopharmacol. 2022;108:108683.35344814 10.1016/j.intimp.2022.108683
38. Kurdi A, Hassan K, Venkataraman B, Rajesh M. Nootkatone confers hepatoprotective and anti-fibrotic actions in a murine model of liver fibrosis by suppressing oxidative stress, inflammation, and apoptosis. J Biochem Mol Toxicol 2018;32(2).
39. He L Yuan H Liang J Hong J Qu C Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis PLoS ONE 2020 15 5 e0233702 10.1371/journal.pone.0233702 32442221
He L, Yuan H, Liang J, Hong J, Qu C. Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis. PLoS ONE. 2020;15(5):e0233702.32442221 10.1371/journal.pone.0233702
40. Chen S Guo H Xie M Zhou C Zheng M Neutrophil: an emerging player in the occurrence and progression of metabolic associated fatty liver disease Int Immunopharmacol 2021 97 107609 10.1016/j.intimp.2021.107609 33887577
Chen S, Guo H, Xie M, Zhou C, Zheng M. Neutrophil: an emerging player in the occurrence and progression of metabolic associated fatty liver disease. Int Immunopharmacol. 2021;97:107609.33887577 10.1016/j.intimp.2021.107609
41. Rensen SS Bieghs V Xanthoulea S Arfianti E Bakker JA Shiri-Sverdlov R Hofker MH Greve JW Buurman WA Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice PLoS ONE 2012 7 12 e52411 10.1371/journal.pone.0052411 23285030
Rensen SS, Bieghs V, Xanthoulea S, Arfianti E, Bakker JA, Shiri-Sverdlov R, Hofker MH, Greve JW, Buurman WA. Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. PLoS ONE. 2012;7(12):e52411.23285030 10.1371/journal.pone.0052411
42. Mirea AM Toonen EJM van den Munckhof I Munsterman ID Tjwa E Jaeger M Oosting M Schraa K Rutten JHW van der Graaf M Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes Mol Med 2019 25 1 16 10.1186/s10020-019-0084-3 31046673
Mirea AM, Toonen EJM, van den Munckhof I, Munsterman ID, Tjwa E, Jaeger M, Oosting M, Schraa K, Rutten JHW, van der Graaf M, et al. Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Mol Med. 2019;25(1):16.31046673 10.1186/s10020-019-0084-3
43. Ou R Liu J Lv M Wang J Wang J Zhu L Zhao L Xu Y Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice Endocrine 2017 57 1 72 82 10.1007/s12020-017-1323-4 28508193
Ou R, Liu J, Lv M, Wang J, Wang J, Zhu L, Zhao L, Xu Y. Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice. Endocrine. 2017;57(1):72–82.28508193 10.1007/s12020-017-1323-4
44. Hoekstra M Van Eck M High-density lipoproteins and non-alcoholic fatty liver disease Atheroscler Plus 2023 53 33 41 10.1016/j.athplu.2023.08.001 37663008
Hoekstra M, Van Eck M. High-density lipoproteins and non-alcoholic fatty liver disease. Atheroscler Plus. 2023;53:33–41.37663008 10.1016/j.athplu.2023.08.001
45. McCullough A Previs SF Dasarathy J Lee K Osme A Kim C Ilchenko S Lorkowski SW Smith JD Dasarathy S HDL flux is higher in patients with nonalcoholic fatty liver disease Am J Physiol Endocrinol Metab 2019 317 5 E852 62 10.1152/ajpendo.00193.2019 31503515
McCullough A, Previs SF, Dasarathy J, Lee K, Osme A, Kim C, Ilchenko S, Lorkowski SW, Smith JD, Dasarathy S, et al. HDL flux is higher in patients with nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab. 2019;317(5):E852–62.31503515 10.1152/ajpendo.00193.2019
46. Murphy AJ Woollard KJ Suhartoyo A Stirzaker RA Shaw J Sviridov D Chin-Dusting JP Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation Arterioscler Thromb Vasc Biol 2011 31 6 1333 41 10.1161/ATVBAHA.111.226258 21474825
Murphy AJ, Woollard KJ, Suhartoyo A, Stirzaker RA, Shaw J, Sviridov D, Chin-Dusting JP. Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol. 2011;31(6):1333–41.21474825 10.1161/ATVBAHA.111.226258
47. Curcic S Holzer M Frei R Pasterk L Schicho R Heinemann A Marsche G Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL Biochim Biophys Acta 2015 1851 2 184 93 10.1016/j.bbalip.2014.11.010 25463476
Curcic S, Holzer M, Frei R, Pasterk L, Schicho R, Heinemann A, Marsche G. Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL. Biochim Biophys Acta. 2015;1851(2):184–93.25463476 10.1016/j.bbalip.2014.11.010
48. Zhao B Liu Y Yang Y He J Association of systemic Immune-inflammation index with non-alcoholic fatty liver disease: a Population-based cross-sectional study Risk Manag Healthc Policy 2023 16 1581 92 10.2147/RMHP.S419183 37605743
Zhao B, Liu Y, Yang Y, He J. Association of systemic Immune-inflammation index with non-alcoholic fatty liver disease: a Population-based cross-sectional study. Risk Manag Healthc Policy. 2023;16:1581–92.37605743 10.2147/RMHP.S419183
49. Yu C He S Kuang M Wang C Huang X Sheng G Zou Y Association between weight-adjusted waist index and non-alcoholic fatty liver disease: a population-based study BMC Endocr Disord 2024 24 1 22 10.1186/s12902-024-01554-z 38369482
Yu C, He S, Kuang M, Wang C, Huang X, Sheng G, Zou Y. Association between weight-adjusted waist index and non-alcoholic fatty liver disease: a population-based study. BMC Endocr Disord. 2024;24(1):22.38369482 10.1186/s12902-024-01554-z
50. Xi WF Yang AM Association between cardiometabolic index and controlled attenuation parameter in U.S. adults with NAFLD: findings from NHANES (2017–2020) Lipids Health Dis 2024 23 1 40 10.1186/s12944-024-02027-x 38326824
Xi WF, Yang AM. Association between cardiometabolic index and controlled attenuation parameter in U.S. adults with NAFLD: findings from NHANES (2017–2020). Lipids Health Dis. 2024;23(1):40.38326824 10.1186/s12944-024-02027-x
